Gene

NTRK1

neurotrophic receptor tyrosine kinase 1

Explore in graph →CI-GENE-00017359HGNC:8031 ENSG00000198400 NCBI 4914 CIViC Cancer geneApproved

Curated evidence

Clinical evidence (101)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–50 of 101 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
NTRK1 Fusion1
Entrectinib	GlioblastomaCURATED_BROADER	Predictive	C	Supports Sensitivity Response	1	submitted

Cohorts

Alteration frequency by cohort (114)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

gdcObserved114 cohort rows (showing 50, sorted by frequency) · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Liver Hepatocellular Carcinoma TCGA-LIHC	Hepatocellular Carcinoma

Literature

Linked publications (38)

25 per page, newest first.

pubmedPublishedShowing 1–25 of 38 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
· Lancet Oncol · 2020 · PMID 31838007 · validated civic_curation pubmed
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.
· N Engl J Med · 2018 · PMID 29466156 · validated civic_curation pubmed
Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
· Lancet Oncol · 2018 · PMID 29606586 · validated civic_curation pubmed
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).
· Cancer Discov · 2017 · PMID 28183697

NTRK1 Fusion19
(diagnostic)	NTRK-Rearranged Spindle Cell NeoplasmALIAS	Diagnostic	C	Supports Positive	4	accepted	EID6391 A 14-month-old boy presented with a slow-growing, asymptomatic back plaque, which was biopsied and found to have S100 positivity, sparse CD34 staining, and no significant mitotic activity, nuclear ple… (full text at CIViC) PMID 29892662 · Bartenstein et al., 2018 · Open in CIViC	civic
〃	Spitzoid Melanoma	Diagnostic	C	Supports Positive	3	accepted	EID8904 A total of 140 Spitzoid neoplasm cases were analyzed by FISH and/or targeted DNA and RNA sequencing (n=38). Mutually exclusive kinase fusions were found in 72 cases. NTRK1 fusions were observed in 23 … (full text at CIViC) PMID 24445538 · Wiesner et al., 2014 · Open in CIViC	civic
〃	NTRK-Rearranged Spindle Cell NeoplasmALIAS	Diagnostic	C	Supports Positive	3	accepted	EID11576 A 31-year-old female presented with a pigmented nodule on her scalp that enlarged in size over a 2-year period. Biopsy demonstrated a fascicular proliferation of bland spindle cells within the dermis … (full text at CIViC) PMID 32519338 · Panse et al., 2021 · Open in CIViC	civic
〃	NTRK-Rearranged Spindle Cell NeoplasmALIAS	Diagnostic	C	Supports Positive	3	accepted	EID11577 A 21-year-old man demonstrated intermittent abdominal pain, and a CT scan revealed an abnormal paraspinal lesion. Biopsy revealed a spindle cell mesenchymal tumor with monotonous, bland spindle cells … (full text at CIViC) PMID 32782782 · Dupuis et al., 2020 · Open in CIViC	civic
〃	NTRK-Rearranged Spindle Cell NeoplasmALIAS	Diagnostic	C	Supports Positive	3	accepted	EID11650 A 3-year-old girl presented with spots on her right buttock that evolved into lumps. Magnetic resonance imaging showed diffuse subcutaneous tissue thickening without significant involvement of underly… (full text at CIViC) PMID 32299759 · Malik et al., 2020 · Open in CIViC	civic
(oncogenic)	Spitzoid Melanoma	Oncogenic	D	Supports Oncogenicity	3	accepted	EID8903 The in-frame LMNA-NTRK1 fusion (exon 2 & exon 11) with intact kinase domain was found and confirmed by next generation sequencing, RT-PCR, FISH, and/or immunohistochemistry in 3 Spitz neoplasm cases. … (full text at CIViC) PMID 24445538 · Wiesner et al., 2014 · Open in CIViC	civic
〃	Malignant Colorectal NeoplasmCURATED_BROADER	Oncogenic	D	Supports Oncogenicity	1	accepted	EID8901 FISH of the tumor and patient derived xenograft of a 75-year-old with metastatic colorectal cancer that spread to the liver indicated NTRK1 involvement. 5’RACE PCR discovered a novel LMNA-NTRK1 fusion… (full text at CIViC) PMID 26563355 · Sartore-Bianchi et al., 2016 · Open in CIViC	civic
Crizotinib	Infantile FibrosarcomaALIAS	Predictive	C	Supports Sensitivity Response	3	accepted	EID8878 A mass found at birth in a patient’s left arm became enlarged at age 2 and was resected and characterized as a high-grade spindle cell sarcoma. FISH and RT-PCR did not detect any common sarcoma transl… (full text at CIViC) PMID 30709876 · Bender et al., 2019 · Open in CIViC	civic
Entrectinib	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	C	Supports Sensitivity Response	4	accepted	EID8900 After disease progression with no objective response to therapy, a 75-year-old with metastatic colorectal cancer that spread to the liver displayed elevated NTRK1 expression in both primary tumor and … (full text at CIViC) PMID 26563355 · Sartore-Bianchi et al., 2016 · Open in CIViC	civic
〃	Colorectal Adenocarcinoma	Predictive	C	Supports Sensitivity Response	3	accepted	EID2960 A gene fusion between exon 11 of LMNA and exon 10 of NTRK1 was observed in a patient with metastatic colorectal cancer after therapy with first-line FOLFOX, second-line FOLFIRI/cetuximab, and third-li… (full text at CIViC) PMID 26546295 · Russo et al., 2016 · Open in CIViC	civic
〃	NTRK-Rearranged Spindle Cell NeoplasmALIAS	Predictive	C	Supports Sensitivity Response	3	accepted	EID11578 A 21-year-old man demonstrated intermittent abdominal pain, and a CT scan revealed an abnormal paraspinal lesion. IHC was positive for CD34, S-100, and pan-TRK and negative for Sox10. Anchored multip… (full text at CIViC) PMID 32782782 · Dupuis et al., 2020 · Open in CIViC	civic
〃	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	3	accepted	EID10095 BaF3 cells were transduced with a number of NTRK fusions. IC50 values were measured following treatment with entrectinib: TPM3-NTRK1 (2.5nM), LMNA-NTRK1 (1.4nM), ETV6-NTRK1 (2.5nM), VCL-NTRK2 (4.3nM),… (full text at CIViC) PMID 26884591 · Drilon et al., 2016 · Open in CIViC	civic
〃	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	3	accepted	EID11354 In a head-to-head comparison of 4 NTRK inhibitors (larotrectinib, entrectinib, repotrectinib, and selitrectinib) with Ba/F3 cells harboring LMNA::NTRK1 with or without kinase domain mutations, the ent… (full text at CIViC) PMID 34625502 · Murray et al., 2021 · Open in CIViC	civic
Larotrectinib	Sarcoma	Predictive	C	Supports Sensitivity Response	3	accepted	EID6100 One Patient with soft tissue sarcoma and a NTRK1-LMNA fusion had a partial response with larotrectinib. Treatment was done within a multicentre, open-label, phase 1/2 study and enrolled infants, child… (full text at CIViC) PMID 29606586 · Laetsch et al., 2018 · Open in CIViC	civic
〃	Solid NeoplasmCURATED_BROADER	Predictive	C	Supports Sensitivity Response	3	accepted	EID9588 One patient was identified with a LMNA-NTRK1 positive tumor in this Phase I study (NCT02122913), which involved 70 heavily pretreated patients with a median age of 59.5 years, with multiple solid tumo… (full text at CIViC) PMID 30624546 · Hong et al., 2019 · Open in CIViC	civic
〃	Sarcoma	Predictive	C	Supports Sensitivity Response	2	accepted	EID2955 LOXO-101 is an orally administered inhibitor of the TRK kinase and is highly selective only for the TRK family of receptors. The tumor of a 41-year-old woman with soft-tissue sarcoma metastatic to the… (full text at CIViC) PMID 26216294 · Doebele et al., 2015 · Open in CIViC	civic
〃	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	2	accepted	EID11349 In a head-to-head comparison of 4 NTRK inhibitors (larotrectinib, entrectinib, repotrectinib, and selitrectinib) with Ba/F3 cells harboring LMNA::NTRK1 with or without kinase domain mutations, the fir… (full text at CIViC) PMID 34625502 · Murray et al., 2021 · Open in CIViC	civic
Repotrectinib	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	3	accepted	EID11346 In a head-to-head comparison of 4 NTRK inhibitors (larotrectinib, entrectinib, repotrectinib, and selitrectinib) with Ba/F3 cells harboring LMNA::NTRK1 with or without kinase domain mutations, repotre… (full text at CIViC) PMID 34625502 · Murray et al., 2021 · Open in CIViC	civic
TRK Inhibitor	Spindle Cell Sarcoma	Predictive	C	Supports Sensitivity Response	3	accepted	EID8902 A 40-year-old patient with a left calf mass revealed by biopsy to be a low grade myxoid spindle cell carcinoma underwent surgery and radiotherapy. Over a 5-year period, the patient experienced 3 lung … (full text at CIViC) PMID 32050835 · So et al., 2020 · Open in CIViC	civic

NTRK1 Fusion + NTRK1 F589L3
Entrectinib	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	3	accepted	EID11355 In a head-to-head comparison of 4 NTRK inhibitors (larotrectinib, entrectinib, repotrectinib, and selitrectinib) with Ba/F3 cells harboring LMNA::NTRK1 with or without kinase domain mutations, the ent… (full text at CIViC) PMID 34625502 · Murray et al., 2021 · Open in CIViC	civic
Larotrectinib	Malignant NeoplasmALIAS	Predictive	D	Supports Resistance	3	accepted	EID11351 In a head-to-head comparison of 4 NTRK inhibitors (larotrectinib, entrectinib, repotrectinib, and selitrectinib) with Ba/F3 cells harboring LMNA::NTRK1 with or without kinase domain mutations, the fir… (full text at CIViC) PMID 34625502 · Murray et al., 2021 · Open in CIViC	civic
Repotrectinib	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	3	accepted	EID11348 In a head-to-head comparison of 4 NTRK inhibitors (larotrectinib, entrectinib, repotrectinib, and selitrectinib) with Ba/F3 cells harboring LMNA::NTRK1 with or without kinase domain mutations, repotre… (full text at CIViC) PMID 34625502 · Murray et al., 2021 · Open in CIViC	civic

NTRK1 Fusion + NTRK1 G595R3
Entrectinib	Malignant NeoplasmALIAS	Predictive	D	Supports Resistance	3	accepted	EID11356 In a head-to-head comparison of 4 NTRK inhibitors (larotrectinib, entrectinib, repotrectinib, and selitrectinib) with Ba/F3 cells harboring LMNA::NTRK1 with or without kinase domain mutations, entrec… (full text at CIViC) PMID 34625502 · Murray et al., 2021 · Open in CIViC	civic
Larotrectinib	Malignant NeoplasmALIAS	Predictive	D	Supports Resistance	3	accepted	EID11350 In a head-to-head comparison of 4 NTRK inhibitors (larotrectinib, entrectinib, repotrectinib, and selitrectinib) with Ba/F3 cells harboring LMNA::NTRK1 with or without kinase domain mutations, the fir… (full text at CIViC) PMID 34625502 · Murray et al., 2021 · Open in CIViC	civic
Repotrectinib	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	3	accepted	EID11347 In a head-to-head comparison of 4 NTRK inhibitors (larotrectinib, entrectinib, repotrectinib, and selitrectinib) with Ba/F3 cells harboring LMNA::NTRK1 with or without kinase domain mutations, repotre… (full text at CIViC) PMID 34625502 · Murray et al., 2021 · Open in CIViC	civic

NTRK1 Fusion + NTRK1 F589L + NTRK1 G595R3
Entrectinib	Malignant NeoplasmALIAS	Predictive	D	Supports Resistance	3	accepted	EID11358 In a head-to-head comparison of 4 NTRK inhibitors (larotrectinib, entrectinib, repotrectinib, and selitrectinib) with Ba/F3 cells harboring LMNA::NTRK1 with or without kinase domain mutations, entrec… (full text at CIViC) PMID 34625502 · Murray et al., 2021 · Open in CIViC	civic
Larotrectinib	Malignant NeoplasmALIAS	Predictive	D	Supports Resistance	3	rejected	EID11352 In a head-to-head comparison of 4 NTRK inhibitors (larotrectinib, entrectinib, repotrectinib, and selitrectinib) with Ba/F3 cells harboring LMNA::NTRK1 with or without kinase domain mutations, larotre… (full text at CIViC) PMID 34625502 · Murray et al., 2021 · Open in CIViC	civic
〃	Malignant NeoplasmALIAS	Predictive	D	Supports Resistance	3	accepted	EID11353 In a head-to-head comparison of 4 NTRK inhibitors (larotrectinib, entrectinib, repotrectinib, and selitrectinib) with Ba/F3 cells harboring LMNA::NTRK1 with or without kinase domain mutations, larotre… (full text at CIViC) PMID 34625502 · Murray et al., 2021 · Open in CIViC	civic

NTRK1 Fusion + NTRK1 G667C2
Entrectinib	Malignant NeoplasmALIAS	Predictive	D	Supports Resistance	3	accepted	EID11357 In a head-to-head comparison of 4 NTRK inhibitors (larotrectinib, entrectinib, repotrectinib, and selitrectinib) with Ba/F3 cells harboring LMNA::NTRK1 with or without kinase domain mutations, entrec… (full text at CIViC) PMID 34625502 · Murray et al., 2021 · Open in CIViC	civic
Larotrectinib	Malignant NeoplasmALIAS	Predictive	D	Supports Resistance	3	accepted	EID11359 In a head-to-head comparison of 4 NTRK inhibitors (larotrectinib, entrectinib, repotrectinib, and selitrectinib) with Ba/F3 cells harboring LMNA::NTRK1 with or without kinase domain mutations, the fir… (full text at CIViC) PMID 34625502 · Murray et al., 2021 · Open in CIViC	civic

NTRK1 Fusion3
(oncogenic)	Lung Squamous Cell Carcinoma	Oncogenic	C	Supports Oncogenicity	1	submitted	EID13048 A retrospective study of tumors sequenced through the Veterans Health Administration National Precision Oncology Program identified NTRK rearrangements in 25 of 22,450 solid tumors. Twelve patients wi… (full text at CIViC) PMID 36926986 · Zhou et al., 2023 · Open in CIViC	civic
〃	Uterine Corpus Endometrial CarcinomaUNRESOLVED	Oncogenic	C	Supports Oncogenicity	1	submitted	EID13057 Hartmaier et al. performed targeted hybrid-capture next-generation sequencing of 18,004 adult solid tumors and identified a novel LRRC71::NTRK1 fusion in one uterine corpus endometrial carcinoma. The … (full text at CIViC) PMID 28235761 · Hartmaier et al., 2017 · Open in CIViC	civic
〃	Lung Adenocarcinoma	Oncogenic	C	Supports Oncogenicity	1	submitted	EID13058 Xu et al. retrospectively analyzed paired pre- and post-EGFR tyrosine kinase inhibitor samples from 3,873 patients with EGFR-mutant lung adenocarcinoma and identified an acquired LRRC71::NTRK1 fusion … (full text at CIViC) PMID 31372039 · Xu et al., 2019 · Open in CIViC	civic

NTRK1 Amplification2
Larotrectinib	Esophageal Carcinoma	Predictive	C	Supports Sensitivity Response	3	accepted	EID12120 A 71-year-old male with esophageal carcinoma harboring NTRK1 amplification, based on FoundationOne CDx profiling test, was treated with larotrectinib. Treatment with larotrectinib led to a shrinkage o… (full text at CIViC) PMID 32323889 · Hempel et al., 2020 · Open in CIViC	civic
〃	Solid NeoplasmCURATED_BROADER	Predictive	C	Supports Sensitivity Response	2	accepted	EID10170 In a phase I study of larotrectinib in 67 patients with solid tumours, 8 patients were recorded as having objective response. 7 of these harboured NTRK fusions, and one had a NTRK1 amplification. This… (full text at CIViC) PMID 30624546 · Hong et al., 2019 · Open in CIViC	civic